An observational study in Myelodysplastic Syndromes, Anemia and Hemopathies, sponsored by Rennes University Hospital. Terminated at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-07.
Sponsored by Rennes University Hospital · Observational
Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.
Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. Thus, only 50-60% of patients with multiple myeloma or non-Hodgkin lymphoma respond to ESAs. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.
1,317 studies on the registry are indexed under Preleukemia; 57 are open to participants now.
This study's enrollment of 30 is below the median of 114 across 116 observational studies indexed under Preleukemia.
Browse Preleukemia studies →Rennes University Hospital is the lead sponsor of 440 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Non-myeloid haemopathy or Myelodysplastic Syndromes patients with anemia, who needs ESAs treatment
Exclusion Criteria:
response to erythropoietin
* Complete response : increase of 2g/dl of erythropoietin rate or stopping of transfusion requirements. * Partial response : increase of 1 to 2g/dl rate of erythropoietin or 50% reduction of transfusion requirements.
Time frame: 12 weeks
endogenous erythropoietin rate
Time frame: Within 8 days before inclusion
hemoglobin rate
Weeks 0 = first ESAs injection
Time frame: Weeks 0,4,8 and 12
Number of transfusions during the duration of the study
Time frame: 12 weeks
This study is terminated, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rennes University Hospital